Company / Shareholders' Equity
AIM ImmunoTech Inc. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$9.8M
FY2025
5-year range
-$9.8M / $61.3M
FY2021-FY2025
Trend
-195.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
AIM ImmunoTech Inc. reports negative total equity of -$10M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$10M in FY2025.
Declined from $38M to -$10M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- AIM ImmunoTech Inc.'s shareholders' equity has declined for 4 consecutive years.
- In FY2025, shareholders' equity decreased 195.6% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -71.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$9.8M | -195.6% |
| FY2024 | $10.2M | -73.4% |
| FY2023 | $38.5M | -32.4% |
| FY2022 | $56.9M | -7.2% |
| FY2021 | $61.3M | +0.0% |
| FY2020 | $61.3M | +356.0% |
| FY2019 | $13.4M | +140.9% |
| FY2018 | $5.6M | -64.0% |
| FY2017 | $15.5M | +0.0% |
| FY2016 | $15.5M | -23.9% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026